Minimal clinically important difference for the 6-min walk test: literature review and application to Morquio A syndrome.

about

Minimal clinically important difference for the 6-min walk test: literature review and application to Morquio A syndrome.

Item

http://www.wikidata.org/entity/Q38820447

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Minimal clinically important d ...... ication to Morquio A syndrome.

@en

type

Item

label

Minimal clinically important d ...... ication to Morquio A syndrome.

@en

prefLabel

Minimal clinically important d ...... ication to Morquio A syndrome.

@en

P1476

Minimal clinically important d ...... ication to Morquio A syndrome.

@en

P2093

Ian Noble

http://www.w3.org/2001/XMLSchema#string

Kathryn Evans

http://www.w3.org/2001/XMLSchema#string

Kaustuv Bhattacharya

http://www.w3.org/2001/XMLSchema#string

Roberto Giugliani

http://www.w3.org/2001/XMLSchema#string

Rudolf Schrover

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 4.0 International

P2860

The 6 minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important difference

The clinical relevance of outcomes used in late-onset Pompe disease: can we do better?

The 6-minute walk test and other clinical endpoints in duchenne muscular dystrophy: reliability, concurrent validity, and minimal clinically important differences from a multicenter study.

Burden of disease in patients with Morquio A syndrome: results from an international patient-reported outcomes survey.

The minimal important difference of exercise tests in severe COPD.

ATS statement: guidelines for the six-minute walk test.

Efficacy and safety of enzyme replacement therapy with BMN 110 (elosulfase alfa) for Morquio A syndrome (mucopolysaccharidosis IVA): a phase 3 randomised placebo-controlled study.

Multi-domain impact of elosufase alfa in Morquio A syndrome in the pivotal phase III trial.

Measurement of health status. Ascertaining the minimal clinically important difference.

Understanding the minimum clinically important difference: a review of concepts and methods.

P2888

s13023-017-0633-1

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.1186/S13023-017-0633-1

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P5008

ScienceSource

P577

2017-04-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1084955239

http://www.w3.org/2001/XMLSchema#string

P698

28441951

http://www.w3.org/2001/XMLSchema#string

P921

Morquio Syndrome

P932

5405472

http://www.w3.org/2001/XMLSchema#string